British pharmaceutical giant GSK on Wednesday committed to investing at least 30 billion in U.S. research and developing (R&D) and manufacturing over the coming five years.The investment includes 1.2 billion toward advanced manufacturing, AI and advanced digital technologies to deliver "next-generation biopharma factories and laboratories in the United States," the drug maker said.The investment commitment comes as President Donald Trump is in the U.K. for a three-day state visit."This week's State Visit ...